Quarterly report pursuant to Section 13 or 15(d)

Acquisition

v3.21.2
Acquisition
9 Months Ended
Sep. 30, 2021
Acquisition [Abstract]  
ACQUISITION

4 — ACQUISITION

 

Purnovate, Inc. Acquisition – Related Party

 

On January 26, 2021 the Company completed its business acquisition of 100% of the equity interests of Purnovate, Inc. (“Purnovate”), pursuant to the Equity Purchase Agreement, dated December 7, 2020, as amended. Mr. Stilley, Adial’s CEO, owned 28.73% of the membership interests in Purnovate and, therefore, the acquisition of Purnovate is considered a related party transaction. The acquisition of Purnovate included an in-place workforce comprised of four employees, ongoing research and development projects and pending patents, certain net working capital assets and an assumed operating lease for laboratory and office space (“Assumed Lease”).

 

Purnovate began occupying the premises of the Assumed Lease in January, 2020 and, as a term of its lease, gained access and use to a significant library of chemical compounds and certain laboratory equipment had been abandoned by a prior tenant. On January 19, 2021, Purnovate, modified and agreed to amend the lease agreement with the landlord (a third party) of the Assumed Lease, which transferred legal title to Purnovate for all assets on the premises of the Assumed Lease while simultaneously extending its term. The Company concluded that the Purnovate Lease Amendment was completed for the benefit of the Company and therefore the acquisition of the assets were considered a separate transaction and apart from the acquisition of Purnovate in accordance with ASC 805-10-25-21.

 

The purchase price of Purnovate consisted of cash consideration of $350,000 (excluding a $350,000 initial working capital loan to Purnovate, which was assumed by Adial at acquisition through its ownership of Purnovate, Purnovate’s liability and Adial’s asset being eliminated in consolidation), the issuance 699,980 shares of Adial common stock ($2.34 at date of closing, less a discount of 35% for a discount for lack of marketability related to the restrictions on the stock-based consideration) and contingent consideration for (i) certain development milestones in an aggregate amount of up to $2,100,000 for the first time any product or compound has achieved the relevant milestone within forty five (45) days after such occurrence (ii) milestones in an aggregate amount of up to $20,000,000 for each compound commercialized, and (iii) royalties of 3.0% of Net Sales (as defined in the Purchase Agreement). The equity consideration was placed into escrow to secure certain indemnification and other obligations of Purnovate and the Members and will be released, subject to certain terms.

 

The Company utilized a relative fair value approach to allocate the fair value of the assets acquired in connection with the Purnovate Lease Amendment and the fair value of Purnovate’s business to the purchase price of Purnovate. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. The estimated fair value of net assets acquired, including the allocation of the fair value to identifiable assets and liabilities, was determined using established valuation techniques.

 

The estimated fair value of the acquired IPR&D was determined using a method which reflects the present value of the operating cash flows generated by this asset after taking into account the cost to realize the revenue, and an appropriate discount rate to reflect the time value and risk associated with the invested capital. These assets are subject to impairment testing until completion or abandonment of each project.

 

The estimated fair value of the acquired research and development supplies (library of chemical compounds and certain laboratory equipment) was determined by discounting the replacement cost of the supplies for probability of use and salvage value if unused. Book value was determined by assigning a portion of the value of consideration paid to the supplies according to the relative fair value of the supplies compared to the fair value of Purnovate’s business. The Company believes that the book value of the supplies is materially lower than their replacement cost, and that therefore the research and development expenses reported as the supplies are utilized is likely be less than the costs defrayed by their acquisition.

 

Certain adjustments to the assessed fair values of the assets and liabilities made subsequent to the acquisition date, but within the measurement period, which is up to one year, are recorded as adjustments to goodwill. Any adjustments subsequent to the measurement period are recorded in income.

 

In connection with the business acquisition, the Company incurred acquisition costs of approximately $46,000 that were recognized in selling, general and administrative expense.

 

Total consideration paid      
Cash consideration   $ 350,000  
Stock consideration     1,060,150  
Contingent consideration     732,287  
Total     2,142,437  
Less: Assets acquired through Purnovate Lease Amendment        
Research and development supplies     (1,548,397 )
Remaining consideration   $ 594,040  

 

The table below sets forth the allocation of the fair value of the Purnovate Net Acquired Assets and the corresponding line item in the Company’s consolidated balance sheet at the date of acquisition.

 

Cash   $ 380,589  
Property and equipment     6,954  
Lease right of use assets     294,294  
In-process research and development     455,000  
Total identifiable assets acquired     1,136,837  
         
Accounts payable and accrued liabilities     910  
Notes payable     350,000  
Lease liability     294,294  
Paycheck protection program loan     29,088  
Total liabilities assumed     674,292  
         
Total identifiable net assets acquired     462,545  
         
Goodwill     131,495  
Net assets acquired   $ 594,040  

 

The Company’s unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021 include the results of operations of Purnovate since January 26, 2021 during which period Purnovate contributed net losses of approximately $117,000 and $224,000, respectively. On an unaudited pro forma basis, the revenues and net income of the Company assuming the acquisition had occurred on January 1, 2020, are shown below. The unaudited pro forma information does not purport to present what the Company’s actual results would have been had the acquisition occurred on January 1, 2020, nor is the financial information indicative of the results of future operations. Since Purnovate’s contribution to the Company’s loss for the three months ended September 30, 2021 is included in the actual results, a pro forma is not presented here.

 

    Three months
ended
September 30,
2020
 
Net revenue   $
 
Net loss   $ (3,430,010 )

 

    Nine months
ended
September 30,
2021
    Nine months
ended
September 30,
2020
 
Net revenue   $
    $
 
Net loss   $ (13,603,613 )   $ (7,685,312 )